Evofem Biosciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
12400 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
Mailing Address
12400 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
Phone
(858) 550-1900
Fiscal Year End
1231
EIN
208527075
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | October 29, 2025 | View on SEC |
| 8-K Current report of material events | October 20, 2025 | View on SEC |
| 8-K Current report of material events | October 17, 2025 | View on SEC |
Annual Reports
10-K
March 11, 2026
- Phexxi sales increased by a modest 5% to $25 million in 2024, driven by higher prescription demand.
- Net loss improved significantly from $110 million in 2023 to $80 million in 2024 due to cost-cutting measures and revenue growth.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.